XTL Biopharmaceuticals Ltd. (FRA:H2K2)

Germany flag Germany · Delayed Price · Currency is EUR
0.6450
-0.0050 (-0.77%)
At close: Nov 28, 2025
-60.43%
Market Cap7.47M
Revenue (ttm)435.62K
Net Income (ttm)-991.98K
Shares Outn/a
EPS (ttm)-0.00
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volumen/a
Open0.6400
Previous Close0.6500
Day's Range0.6400 - 0.6450
52-Week Range0.6200 - 4.0000
Betan/a
RSI36.50
Earnings DateNov 18, 2025

About XTL Biopharmaceuticals

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren’s syndrome. The company has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1993
Employees 10
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol H2K2
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.